April 15 - 16, 2019
National Institutes of Health Masur Auditorium
Abstract submission deadline: Wednesday, April 10
Advance registration deadline: Tuesday, April 16
The American Association for Cancer Research (AACR) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education activities for physicians.
Credit Designation StatementAACR has designated this live activity for a maximum of 13.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Credit certification for individual sessions may vary, dependent upon compliance with the ACCME Accreditation Criteria. The final number of credits may vary from the maximum number indicated above.
Claiming (CME) CreditPhysicians and other health care professionals seeking AMA PRA Category 1 Credit(s)™ for this live continuing medical education activity must complete the online CME Request for Credit Survey by May 28, 2019. Certificates will only be issued to those who complete the Survey. Your certificate will be sent to you via email after the completion of the activity.
Statement of Educational Need, Target Audience, and Learning ObjectivesThe incredible clinical success of cancer immunotherapies, particularly immune checkpoint inhibitors, has resulted in widespread use across many cancers. As utilization has increased, so too have observations and reports of toxicities, sometimes severe, in nearly every organ system. These immune-related adverse events (irAEs) manifest differently depending on the pathway targeted by the therapy (i.e., CTLA-4 or PD-1/PD-L1), and the emerging use of combination therapies has only increased the frequency of events.
In order to better understand, predict, and treat immunotoxicities in cancer patients, clinicians need to first understand the mechanisms underlying irAEs. Recognizing the similarities to and associations with autoimmune diseases—which share many biologic underpinnings with irAEs—will also be beneficial, as will increased awareness of how irAEs present across multiple organ systems.
The NIH-AACR Cancer, Autoimmunity, and Immunology Conference will bring together world-renowned oncologists, immunologists, rheumatologists, and basic researchers to address these gaps. Attendees will hear about cutting-edge research on immunologic toxicities in the gastrointestinal and neurologic/ocular systems and skin. They will learn how animal models are being used to interrogate the mechanistic bases for irAEs and conventional autoimmunities, and how meta-analyses are being harnessed to determine prevalence of and predict outcomes following irAEs. Emerging topics in autoimmunity and immunotherapy, such as the role of the gut microbiome and potential uses and dangers of cell-based therapies, will also be presented.
With invited speakers presenting case studies and/or recent research on immune-related adverse events across multiple organ systems, this conference will be of interest to oncologists of all subspecialties, as well as immunologists and rheumatologists.
After participating in this CME activity, physicians should be able to:
Disclosure StatementIt is the policy of the AACR that the information presented at AACR CME activities will be unbiased and based on scientific evidence. To help participants make judgments about the presence of bias, AACR will provide information that Scientific Program Committee members and speakers have disclosed about financial relationships they have with commercial entities that produce or market products or services related to the content of this CME activity. This disclosure information
will be made available in the Program/Proceedings of this conference.Questions about CME?Please contact the Office of CME at (215) 440-9300 or email@example.com